Effect of different growth hormone pretreatment times in assisted reproductive therapy for patients with diminished ovarian reserve: A retrospective pilot cohort study.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as an observational study.

This study aimed to evaluate the effect of different growth hormone (GH) pretreatment times in assisted reproductive therapy in patients with diminished ovarian reserve (DOR).

Why It Was Studied

A total of 1459 patients met the criteria and were divided into four groups according to GH pretreatment time as follows: 53 were in the 2-month pretreatment group (GH1), 400 were in the 1-month pretreatment group (GH2), 414 were in the ovulation induction period pretreatment group (GH3), and 592 were in the non-GH pretreatment group (control group).

In addition, GH1, GH2, and GH3 were combined in the GH pretreatment group.

Who Took Part

According to the abstract, 1459 patients were involved.

The age groups tagged for this paper are adults, women only.

How the Study Was Run

In design terms this was a pilot study.

It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.

What Was Measured

Baseline characteristics and treatment outcomes were compared between the groups.

PubMed files the paper under topics including Pilot Projects, Ovarian Reserve, Ovulation Induction, Human Growth Hormone, Reproductive Techniques, Assisted, Pregnancy Rate and Oocyte Retrieval.

What This Means in Plain Language

The paper is a pilot study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 1459 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2024 (Medicine), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.